Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

256 articles about Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

• Cellectar Biosciences Strengthens Management Team With Appointment Of John Friend, M.D. As Chief Medical Officer

  4/13/2017

• Cellectar Biosciences Adds Industry Veterans Douglas Swirsky And Frederick Driscoll To Its Board Of Directors

  4/11/2017

• After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial Of CLR 131 In Multiple Myeloma And Other Blood Cancers

  3/30/2017

• Cellectar Biosciences Further Deepens Intellectual Property Portfolio With Patent Grant For PET Imaging PDC

  3/21/2017

• Cellectar Biosciences Reports 2016 Company Performance And Continued Progress In First Quarter 2017

  3/16/2017

• Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences ’ Intellectual Property Portfolio

  3/14/2017

• Cellectar Biosciences To Host Conference Call On March 15 To Report Fourth Quarter And Year-End 2016 Financial Results And Corporate Performance

  3/9/2017

• Expanding Its Strategic Relationship With Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement

  3/8/2017

• Cellectar Biosciences Provides Phase I Trial Update Of CLR 131 In Multiple Myeloma: Median Progression-Free Survival Extends To 133 Days, Median Overall Survival Reaches 17.7 Months

  2/27/2017

• Upon Successful Completion Of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort Of Its Phase I Clinical Trial Of CLR 131 In Multiple Myeloma

  2/22/2017

• Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating The Capabilities Of The PDC Platform

  1/31/2017

• Cellectar Biosciences Release: Company Announces Additional U.S. Patent Granted For CLR 131 And CLR 125 In A Broad Range Of Solid Tumors

  1/24/2017

• Cellectar Biosciences Announces US And Japanese Patent Allowances For Diagnostic And Optical Imaging PDCs

  12/20/2016

• Cellectar Biosciences Announces USPTO Grants Patent Allowances For Radiotherapeutic Pdcs For A Variety Of Solid Tumor Types

  12/14/2016

• Cellectar Biosciences Announces USPTO Grants Patent For Paclitaxel PDC; Provides Additional Patent Protection For Select Solid Tumors Through 2035

  12/12/2016

• Cellectar Biosciences Presents Poster At The 58th Annual Meeting Of The American Society of Hematology

  12/6/2016

• Cellectar Biosciences Announces Results From The First Two Cohorts Of Its CLR 131 Phase I Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, And Progression Free Survival Similar To Or Better Than Recently Approved Therapies

  12/1/2016

• Cellectar Biosciences Announces Successful Completion Of $9.2 Million Public Offering, Which Includes Full Exercise Of $1.2 Million Over-Allotment Option

  11/30/2016

• Cellectar Biosciences Announces Partnership With Radiopharmaceutical Specialists, CPDC, To Establish Manufacturing Capacity In Anticipation Of CLR 131 Pivotal Trial And Commercial Production

  11/28/2016

• Cellectar Biosciences Announces Pricing Of $8,000,000 Public Offering

  11/23/2016